Advertisement

Assessment of the Abuse Potentiality of Amphetamines and LSD-Like Hallucinogens in Man and its Relationship to Basic Animal Assessment Programs

  • W. R. Martin
Conference paper
Part of the Bayer-Symposium book series (BAYER-SYMP, volume 4)

Abstract

Amphetamine-like stimulants and LSD-like hallucinogens have been adjudged both nationally and internationally to have a significant abuse potentiality. In making a decision about whether a drug has an abuse potentiality similar to that of amphetamine or LSD, the following types of data are helpful: 1. An estimate of the habituating or reinforcing properties of the drug, 2. a characterization of the actions of the drug on the central nervous system and the demonstration of its similarity to the prototype drug, 3. the demonstration of direct tolerance to the drug and cross tolerance to the prototype, as well as cross tolerance to the drug in subjects tolerant to the prototype, and 4. the demonstration of physical dependence and of cross dependence.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Angrist, B., Gershon, S.: Possible dose-response relationships in amphetamine psychosis. In: Zarafonetis, C. J. D. (Ed.): Drug abuse: Proceedings of the International Conference, pp. 263–269. Philadelphia: Lea & Febiger 1972.Google Scholar
  2. Appel, J. B., Freedman, D. X.: Tolerance and cross-tolerance among psychotomimetic drugs. Psychopharmacologia (Berl.) 13, 267–274 (1968).CrossRefGoogle Scholar
  3. Connell, P. H.: Amphetamine psychosis. Maudsley Monograph No. 5. London: Institute of Psychiatry 1958.Google Scholar
  4. Day, M. D., Rand, M. J.: Tachyphylaxis to some sympathomimetic amines in relation to monoamine oxidase. Brit. J. Pharmacol. 21, 84–96 (1963).PubMedGoogle Scholar
  5. Fraser, H. F., Van Horn, G. D., Martin, W. R., Wolbach, A. B., Isbell, H.: Methods for evaluating addiction liability. (A) “Attitude” of opiate addicts toward opiate-like drugs, (B) A short-term “direct” addiction test. J. Pharmacol. exp. Ther. 133, 371–387 (1961).PubMedGoogle Scholar
  6. Freedman, D. X., Aghajanian, G. K., Ornitz, E. M., Rosner, B. S.; Patterns of tolerance to lysergic acid diethylamide and mescaline in rats. Science 127, 1173–1174 (1958).PubMedCrossRefGoogle Scholar
  7. Freedman, D. X., Appel, J. B., Hartman, F. R., Molliver, M. E.: Tolerance to behavioral effects of LSD-25 in rat. J. Pharmacol. exp. Then 143, 309–313 (1964).Google Scholar
  8. Goldberg, L.: Drug abuse in Sweden. Bull. Narcot. 20, 1–31 (1968).Google Scholar
  9. Griffith, J. D., Cavanaugh, J. H., Held, J., Oates, J. A.: Experimental psychosis induced by the administration of d-amphetamine. In: Costa, E., Garattini, S. (Eds.): International Symposium on Amphetamines and Related Compounds; Proceedings of the Mario Negri Institute for Pharmacological Research, Milan, Italy, pp. 897–904. New York: Raven Press 1970.Google Scholar
  10. Haertzen, C.A.: Development of scales based on patterns of drug effects, using the Addiction Research Center Inventory (ARCI). Psychol. Rep. 18, 163–194 (1966).PubMedCrossRefGoogle Scholar
  11. Harrisson, J. W. E., Ambrus, C. M., Ambrus, J. L.: Tolerance of rats toward amphetamine and methamphetamine. J. Amer. pharm. Ass. 41, 539–541 (1952).CrossRefGoogle Scholar
  12. Hill, H. E., Haertzen, C. A., Wolbach, A. B. Jr., Miner, E. J.: The Addiction Research Center Inventory: Standardization of scales which evaluate subjective effects of morphine, amphetamine, pentobarbital, alcohol, LSD-25, pyrahexyl and chlorpromazine. Psychopharmacologia (Berl.) 4, 167–183 (1963).CrossRefGoogle Scholar
  13. Isbell, H.: Comparison of the reactions induced by psilocybin and LSD-25 in man. Psychopharmacologia (Berl.) 1, 29–38 (1959).CrossRefGoogle Scholar
  14. Isbell, H.,HBelleville, R. E., Fraser, H. F., Wirler, A., Logan, C. R.: Studies on lysergic acid diethyl-amide (LSD-25). I. Effects in former morphine addicts and development of tolerance during chronic intoxication. Arch. Neurol. Psychiat. (Chic.) 76, 468–478 (1956).Google Scholar
  15. Isbell, H., Wolbach, A. B., Wikler, A, Miner, E. J.: Cross tolerance between LSD and psilocybin. Psychopharmacologia (Berl.) 2, 147–159 (1961).CrossRefGoogle Scholar
  16. Kramer, J. C.: Some observations on and a review of the effects of high-dose use of amphetamines. In: Zarafonetis,C.J.D. (Ed.): Drug Abuse: Proceedings of the International Conference, pp. 253–261. Philadelphia: Lea & Febiger 1972.Google Scholar
  17. Lewander, T.: Urinary excretion and tissue levels of catecholamines during chronic amphetamine intoxication. Psychopharmacologia (Berl.) 13, 394–407 (1968).CrossRefGoogle Scholar
  18. Martin, W. R., Fades, C. G.: The action of tryptamine on the dog spinal cord and its relationship to the agonistic actions of LSD-like psychotogens. Psychopharmacologia (Berl.) 17, 242–257 (1970).CrossRefGoogle Scholar
  19. Martin, W. R., Fades, C. G.: CCross tolerance to tryptamine in the LSD tolerant dog. Psychopharmacologia (Berl.) 27, 93–98 (1972).CrossRefGoogle Scholar
  20. Martin, W. R.,WSloan, J. W., Sapira, J. D., Jasinski, D. R.: Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine and methylphenidate in man. Clin. Pharmacol. Ther. 12, 245–258 (1971).Google Scholar
  21. Maxwell, R. A., Plummer, A. J., Ross, S.D., Paytas, J. J., Dennis, A. D.: Antihypertensive effect of the central nervous stimulant, methylphenidate. Arch. in Pharmacodyn. 112, 26–35 (1957).Google Scholar
  22. Rosenberg, D. E., Isbell, H., Miner, E. J., Logan, C. R.: The effect of N,N-dimethyltryptamine in human subjects tolerant to lysergic acid diethylamide. Psychopharmacologia (Berl.) 5, 217–227 (1964).CrossRefGoogle Scholar
  23. Rosenberg, D. E.,Dwolbach, A. B., Miner, E. J., Isbell, H.: Observations on direct and cross tolerance with LSD and d-amphetamine in man. Psychopharmacologia (Berl.) 5, 1–15 (1963).Google Scholar
  24. Tormey, J., Lasagna, L.: Relation of thyroid function to acute and chronic effects of amphetamine in the rat. J. Pharmacol. exp. Ther. 128, 201–209 (1960).PubMedGoogle Scholar
  25. Wolbach, A.B., Jr., Miner, E. J., Isbell, H.: Comparison of psilocin with psilocybin, mescaline and LSD-25. Psychopharmacologia (Berl.) 3, 219–223 (1962a).CrossRefGoogle Scholar
  26. Wolbach, A.B., Aisbell, H., Miner, E. J.: Cross tolerance between mescaline and LSD-25; with a comparison of the mescaline and LSD reactions. Psychopharmacologia (Berl.) 3, 1–14 (1962b).Google Scholar

Copyright information

© Springer-Verlag 1973

Authors and Affiliations

  • W. R. Martin
    • 1
  1. 1.National Institute of Mental HealthAddiction Research CenterLexingtonUSA

Personalised recommendations